Kymera Therapeutics, Inc. (KYMR) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day everyone. My name is Sophie and I will be your conference operator today. At this time, I would like to welcome you to the Chimera Therapeutics third quarter 2025 results call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time and you have joined via the webinar, please use the raise hand icon, which can be found at the bottom of your webinar application. If you have joined by phone, please dial star nine on your keypad to raise your hand. At this time, I would like to turn the call over to Justine Konigsberg, Vice President of Investor Relations. Good morning and welcome to Chimera's quarterly update. Joining me this morning are Nello Manolfi, founder, president, and CEO, Jared Golub, our chief medical officer, and Bruce Jacobs, our chief financial officer. Following our prepared remarks, we will open the call to questions from our publishing analysts. If you would like to ask a question, please use the raise hand icon, which can be found at the bottom of your meeting window. And to help us move efficiently through the Q&A session, we ask that you are ready to unmute your line when called on. In addition, we ask that you please limit your question to one and a relevant follow-on to be sure we have enough time to address everyone's questions this morning. Before we begin, I would like to remind you that today's discussion will include forward-looking statements about our future expectations, plans, and prospects. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected. A description of these risks can be found in our most recent 10Q filed with t...